Effects of amlodipine and candesartan on arterial stiffness estimated by cardio-ankle vascular index in patients with essential hypertension: A 24-week study

Current Therapeutic Research - Clinical and Experimental

Volumn 69, Issue 5, 2008, Pages 412-422

  Kurata, Mie ^a   Okura, Takafumi ^a   Watanabe, Sanae ^a   Irita, Jun ^a   Enomoto, Daijiro ^a   Johtoku, Masanori ^a   Miyoshi, Ken ichi ^a   Koresawa, Mitsuko ^a   Fukuoka, Tomikazu ^a   Higaki, Jitsuo ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

amlodipne; arterial stiffness; candesartan; cardio ankle vascular index

Indexed keywords

AMLODIPINE; CANDESARTAN;

ADULT; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTICLE; CARDIO ANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 58149392062     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2008.10.002     Document Type: Article

References (31)

1. Blacher J., Asmar R., Djane S., et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 33 (1999) 1111-1117
2. Laurent S., Boutouyrie P., Asmar R., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37 (2001) 1236-1241
3. Yamashina A., Tomiyama H., Arai T., et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 26 (2003) 615-622
4. Munakata M., Ito N., Nunokawa T., and Yoshinaga K. Utility of automated brachial ankle pulse wave velocity measurements in hypertensive patients. Am J Hypertens 16 (2003) 653-657
5. Imanishi R., Seto S., Toda G., et al. High brachial-ankle pulse wave velocity is an independent predictor of the presence of coronary artery disease in men. Hypertens Res 27 (2004) 71-78
6. Kubozono T., Miyata M., Ueyama K., et al. Clinical significance and reproducibility of new arterial distensibility index. Circ J 71 (2007) 89-94
7. Yambe T., Yoshizawa M., Saijo Y., et al. Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother 58 Suppl 1 (2004) 895-898
8. Shirai K., Utino J., Otsuka K., and Takata M. A novel blood pressure-independent arterial wall stiffness parameter: Cardio-ankle vascular index (CAVI). J Atheroscler Thromb 13 (2006) 101-107
9. Hayashi K., Sato M., Niimi H., et al. Analysis of the constitutive laws of the vascular wall by finite deformation theory [in Japanese]. Iyodenshi To Seitai Kogaku 13 (1975) 293-298
10. Kawasaki T., Takeuchi K., Hasegawa M., et al. Noninvasive measurement of common carotid artery effect with echo phase tracking system. J Japanese College Angiol 22 (1982) 241-248
11. Okura T., Watanabe S., Kurata M., et al. Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. Hypertens Res 30 (2007) 335-340
12. Mizuguchi Y., Oishi Y., Tanaka H., et al. Arterial stiffness is associated with left ventricular diastolic function in patients with cardiovascular risk factors: Early detection with the use of cardio-ankle vascular index and ultrasonic strain imaging. J Card Fail 13 (2007) 744-751
13. Uchida H., Nakamura Y., Kaihara M., et al. Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension [published correction appears in Hypertens Res. 2006;29:295]. Hypertens Res 27 (2004) 545-550
14. JATOS Study Group. The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): Protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res 28 (2005) 513-520
15. Staessen J.A., Fagard R., Thijs L., et al., Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350 (1997) 757-764
16. Hansson L., Hedner T., Lund-Johansen P., et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 356 (2000) 359-365
17. Opie L.H., and Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: Equality of mortality and cardiovascular risk relative to conventional therapy [published correction appears in J Am Coll Cardiol. 2002;39:1409-1410]. J Am Coll Cardiol 39 (2002) 315-322
18. Nissen S.E., Tuzcu E.M., Libby P., et al., CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 292 (2004) 2217-2225
19. Yoshii T., Iwai M., Li Z., et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 29 (2006) 457-466
20. Nilsson J., Sjölund M., Palmberg L., et al. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis 58 (1985) 109-122
21. Ding Y., and Vaziri N.D. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther 292 (2000) 606-609
22. Hasegawa M. Fundamental research on human aortic pulse wave velocity. Jikei Med J 85 (1970) 742-760
23. Cameron J. Estimation of arterial mechanics in clinical practice and as a research technique. Clin Exp Pharmacol Physiol 26 (1999) 285-294
24. Benetos A., Adamopoulos C., Bureau J.M., et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 105 (2002) 1202-1207
25. Brener S.J., Ivanc T.B., Poliszczuk R., et al. Anti hypertensive therapy and regression of coronary artery disease: Insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Ana Heart J 152 (2006) 1059-1063
26. Munakata M., Nagasaki A., Nunokawa T., et al. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 17 (2004) 1050-1055
27. Ichihara A., Hayashi M., Koura Y., et al. Long-term effects of intensive blood-pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens 16 (2003) 959-965
28. Vaziri N.D., Xu Z.G., Shahkarami A., et al. Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-l, MAP kinase, and matrix expressions in obesity. Kidney Int 68 (2005) 2787-2793
29. Sasamura H., Kitamura Y., Nakamura M., et al. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension. Clin Exp Hypertens 28 (2006) 511-520
30. Yambe T., Meng X., Hou X., et al. Cardio-ankle vascular index (CAVI) for the monitoring of the atherosclerosis after heart transplantation. Biomed Pharmacother 59 Suppl 1 (2005) S177-5179
31. Wakabayashi I., and Masuda H. Association of acute-phase reactants with arterial stiffness in patients with type 2 diabetes mellitus. Clin Chim Acta 365 (2006) 230-235